BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 2015;519:247-50. [DOI: 10.1038/nature14035] [Cited by in Crossref: 140] [Cited by in F6Publishing: 123] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Futamura A, Nozawa D, Araki Y, Tamura Y, Tokura S, Kawamoto H, Tokumaru Y, Kakihara S, Aoki T, Ohtake N. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide. Bioorganic & Medicinal Chemistry 2017;25:5203-15. [DOI: 10.1016/j.bmc.2017.07.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Ghani L, Munk CF, Zhang X, Katsube S, Du Y, Cecchetti C, Huang W, Bae HE, Saouros S, Ehsan M, Guan L, Liu X, Loland CJ, Kobilka BK, Byrne B, Chae PS. 1,3,5-Triazine-Cored Maltoside Amphiphiles for Membrane Protein Extraction and Stabilization. J Am Chem Soc 2019;141:19677-87. [PMID: 31809039 DOI: 10.1021/jacs.9b07883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Wacker D, Roth BL. An alerting structure: human orexin receptor 1. Nat Struct Mol Biol 2016;23:265-6. [PMID: 27045444 DOI: 10.1038/nsmb.3198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Corin K, Tegler LT, Koutsopoulos S. G-Protein-Coupled Receptor Expression and Purification. Methods Mol Biol 2021;2178:439-67. [PMID: 33128765 DOI: 10.1007/978-1-0716-0775-6_28] [Reference Citation Analysis]
6 DeLaney K, Buchberger A, Li L. Identification, Quantitation, and Imaging of the Crustacean Peptidome. Methods Mol Biol 2018;1719:247-69. [PMID: 29476517 DOI: 10.1007/978-1-4939-7537-2_17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
7 Shang Y, Filizola M. Opioid receptors: Structural and mechanistic insights into pharmacology and signaling. Eur J Pharmacol 2015;763:206-13. [PMID: 25981301 DOI: 10.1016/j.ejphar.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
8 Crépin T, Swale C, Monod A, Garzoni F, Chaillet M, Berger I. Polyproteins in structural biology. Curr Opin Struct Biol 2015;32:139-46. [PMID: 25996897 DOI: 10.1016/j.sbi.2015.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
9 Hellmann J, Drabek M, Yin J, Gunera J, Pröll T, Kraus F, Langmead CJ, Hübner H, Weikert D, Kolb P, Rosenbaum DM, Gmeiner P. Structure-based development of a subtype-selective orexin 1 receptor antagonist. Proc Natl Acad Sci U S A 2020;117:18059-67. [PMID: 32669442 DOI: 10.1073/pnas.2002704117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
11 Shihoya W, Nishizawa T, Yamashita K, Inoue A, Hirata K, Kadji FMN, Okuta A, Tani K, Aoki J, Fujiyoshi Y, Doi T, Nureki O. X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog. Nat Struct Mol Biol 2017;24:758-64. [PMID: 28805809 DOI: 10.1038/nsmb.3450] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
12 Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, Mcdonald TP, O’brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Bioorganic & Medicinal Chemistry Letters 2016;26:5809-14. [DOI: 10.1016/j.bmcl.2016.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
13 Piscitelli CL, Kean J, de Graaf C, Deupi X. A Molecular Pharmacologist's Guide to G Protein-Coupled Receptor Crystallography. Mol Pharmacol 2015;88:536-51. [PMID: 26152196 DOI: 10.1124/mol.115.099663] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
14 Christopher JA, Aves SJ, Brown J, Errey JC, Klair SS, Langmead CJ, Mace OJ, Mould R, Patel JC, Tehan BG, Zhukov A, Marshall FH, Congreve M. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. Med Chem Commun 2015;6:947-55. [DOI: 10.1039/c5md00027k] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
15 Ehrenmann J, Schöppe J, Klenk C, Rappas M, Kummer L, Doré AS, Plückthun A. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nat Struct Mol Biol 2018;25:1086-92. [PMID: 30455434 DOI: 10.1038/s41594-018-0151-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
16 Di Giglio MG, Muttenthaler M, Harpsøe K, Liutkeviciute Z, Keov P, Eder T, Rattei T, Arrowsmith S, Wray S, Marek A, Elbert T, Alewood PF, Gloriam DE, Gruber CW. Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide. Sci Rep 2017;7:41002. [PMID: 28145450 DOI: 10.1038/srep41002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
17 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, Partridge AT, Minnick C, Breslin MJ, Rudd MT, Stachel SJ, Rada VL, Kern JC, Armacost KA, Hollingsworth SA, O'Brien JA, Hall DL, McDonald TP, Strickland C, Brooun A, Soisson SM, Hollenstein K. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun 2021;12:815. [PMID: 33547286 DOI: 10.1038/s41467-021-21087-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
19 Blundell CD, Nowak T, Watson MJ. Measurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery. Elsevier; 2016. pp. 45-147. [DOI: 10.1016/bs.pmch.2015.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B. Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. Nature 2018;556:520-4. [PMID: 29670288 DOI: 10.1038/s41586-018-0046-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 15.3] [Reference Citation Analysis]
21 Columbus L. Post-expression strategies for structural investigations of membrane proteins. Curr Opin Struct Biol 2015;32:131-8. [PMID: 25951412 DOI: 10.1016/j.sbi.2015.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
22 Suno R, Kimura KT, Nakane T, Yamashita K, Wang J, Fujiwara T, Yamanaka Y, Im D, Horita S, Tsujimoto H, Tawaramoto MS, Hirokawa T, Nango E, Tono K, Kameshima T, Hatsui T, Joti Y, Yabashi M, Shimamoto K, Yamamoto M, Rosenbaum DM, Iwata S, Shimamura T, Kobayashi T. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA. Structure 2018;26:7-19.e5. [DOI: 10.1016/j.str.2017.11.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
23 Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 2018;23:E2926. [PMID: 30423961 DOI: 10.3390/molecules23112926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Grisshammer R. New approaches towards the understanding of integral membrane proteins: A structural perspective on G protein-coupled receptors. Protein Sci 2017;26:1493-504. [PMID: 28547763 DOI: 10.1002/pro.3200] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
25 Yin J, Chapman K, Clark LD, Shao Z, Borek D, Xu Q, Wang J, Rosenbaum DM. Crystal structure of the human NK1 tachykinin receptor. Proc Natl Acad Sci U S A 2018;115:13264-9. [PMID: 30538204 DOI: 10.1073/pnas.1812717115] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
26 Tikhonova IG. Application of GPCR Structures for Modelling of Free Fatty Acid Receptors. Handb Exp Pharmacol 2017;236:57-77. [PMID: 27757764 DOI: 10.1007/164_2016_52] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
27 Eddy MT, Didenko T, Stevens RC, Wüthrich K. β2-Adrenergic Receptor Conformational Response to Fusion Protein in the Third Intracellular Loop. Structure 2016;24:2190-7. [PMID: 27839952 DOI: 10.1016/j.str.2016.09.015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
28 DeLaney K, Buchberger AR, Atkinson L, Gründer S, Mousley A, Li L. New techniques, applications and perspectives in neuropeptide research. J Exp Biol 2018;221:jeb151167. [PMID: 29439063 DOI: 10.1242/jeb.151167] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
29 Shahaf N, Pappalardo M, Basile L, Guccione S, Rayan A. How to Choose the Suitable Template for Homology Modelling of GPCRs: 5-HT7 Receptor as a Test Case. Mol Inform 2016;35:414-23. [PMID: 27546045 DOI: 10.1002/minf.201501029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
30 Xiang J, Chun E, Liu C, Jing L, Al-sahouri Z, Zhu L, Liu W. Successful Strategies to Determine High-Resolution Structures of GPCRs. Trends in Pharmacological Sciences 2016;37:1055-69. [DOI: 10.1016/j.tips.2016.09.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
31 Ehsan M, Du Y, Molist I, Seven AB, Hariharan P, Mortensen JS, Ghani L, Loland CJ, Skiniotis G, Guan L, Byrne B, Kobilka BK, Chae PS. Vitamin E-based glycoside amphiphiles for membrane protein structural studies. Org Biomol Chem 2018;16:2489-98. [PMID: 29564464 DOI: 10.1039/C8OB00270C] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Nagahara T, Saitoh T, Kutsumura N, Irukayama-Tomobe Y, Ogawa Y, Kuroda D, Gouda H, Kumagai H, Fujii H, Yanagisawa M, Nagase H. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem 2015;58:7931-7. [PMID: 26267383 DOI: 10.1021/acs.jmedchem.5b00988] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
33 Jazayeri A, Andrews SP, Marshall FH. Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. Chem Rev 2017;117:21-37. [PMID: 27333206 DOI: 10.1021/acs.chemrev.6b00119] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
34 Costanzi S, Skorski M, Deplano A, Habermehl B, Mendoza M, Wang K, Biederman M, Dawson J, Gao J. Homology modeling of a Class A GPCR in the inactive conformation: A quantitative analysis of the correlation between model/template sequence identity and model accuracy. J Mol Graph Model 2016;70:140-52. [PMID: 27723562 DOI: 10.1016/j.jmgm.2016.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
35 Ehsan M, Ghani L, Du Y, Hariharan P, Mortensen JS, Ribeiro O, Hu H, Skiniotis G, Loland CJ, Guan L, Kobilka BK, Byrne B, Chae PS. New penta-saccharide-bearing tripod amphiphiles for membrane protein structure studies. Analyst 2017;142:3889-98. [PMID: 28913526 DOI: 10.1039/c7an01168g] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
36 Jazayeri A, Dias JM, Marshall FH. From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. J Biol Chem 2015;290:19489-95. [PMID: 26100628 DOI: 10.1074/jbc.R115.668251] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
37 Bae HE, Cecchetti C, Du Y, Katsube S, Mortensen JS, Huang W, Rehan S, Lee HJ, Loland CJ, Guan L, Kobilka BK, Byrne B, Chae PS. Pendant-bearing glucose-neopentyl glycol (P-GNG) amphiphiles for membrane protein manipulation: Importance of detergent pendant chain for protein stabilization. Acta Biomater 2020;112:250-61. [PMID: 32522715 DOI: 10.1016/j.actbio.2020.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Vass M, Kooistra AJ, Verhoeven S, Gloriam D, de Esch IJP, de Graaf C. A Structural Framework for GPCR Chemogenomics: What's In a Residue Number? Methods Mol Biol 2018;1705:73-113. [PMID: 29188559 DOI: 10.1007/978-1-4939-7465-8_4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
39 Liu M, Min T, Zhang H, Liu Y, Wang Z. Pharmacological Characteristics of Porcine Orexin 2 Receptor and Mutants. Front Endocrinol (Lausanne) 2020;11:132. [PMID: 32296386 DOI: 10.3389/fendo.2020.00132] [Reference Citation Analysis]
40 Payandeh J, Volgraf M. Ligand binding at the protein-lipid interface: strategic considerations for drug design. Nat Rev Drug Discov 2021;20:710-22. [PMID: 34257432 DOI: 10.1038/s41573-021-00240-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Clark L, Dikiy I, Rosenbaum DM, Gardner KH. On the use of Pichia pastoris for isotopic labeling of human GPCRs for NMR studies. J Biomol NMR 2018;71:203-11. [PMID: 30121871 DOI: 10.1007/s10858-018-0204-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
42 Ehsan M, Katsube S, Cecchetti C, Du Y, Mortensen JS, Wang H, Nygaard A, Ghani L, Loland CJ, Kobilka BK, Byrne B, Guan L, Chae PS. New Malonate-Derived Tetraglucoside Detergents for Membrane Protein Stability. ACS Chem Biol 2020;15:1697-707. [PMID: 32501004 DOI: 10.1021/acschembio.0c00316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Wu F, Song G, de Graaf C, Stevens RC. Structure and Function of Peptide-Binding G Protein-Coupled Receptors. J Mol Biol 2017;429:2726-45. [PMID: 28705763 DOI: 10.1016/j.jmb.2017.06.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
44 Stauch B, Johansson LC, Cherezov V. Structural insights into melatonin receptors. FEBS J 2020;287:1496-510. [PMID: 31693784 DOI: 10.1111/febs.15128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
45 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
46 Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H. Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors. ChemMedChem 2019;14:965-81. [PMID: 30892823 DOI: 10.1002/cmdc.201900074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Das M, Mahler F, Hariharan P, Wang H, Du Y, Mortensen JS, Patallo EP, Ghani L, Glück D, Lee HJ, Byrne B, Loland CJ, Guan L, Kobilka BK, Keller S, Chae PS. Diastereomeric Cyclopentane-Based Maltosides (CPMs) as Tools for Membrane Protein Study. J Am Chem Soc 2020;142:21382-92. [PMID: 33315387 DOI: 10.1021/jacs.0c09629] [Reference Citation Analysis]
48 Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, Julkunen I, Vuorela A, Vaarala O, Nohynek H, Pasini FL, Montomoli E, Trombetta C, Adams CM, Rothbard J, Steinman L. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015;7:294ra105. [PMID: 26136476 DOI: 10.1126/scitranslmed.aab2354] [Cited by in Crossref: 159] [Cited by in F6Publishing: 132] [Article Influence: 26.5] [Reference Citation Analysis]
49 Das M, Du Y, Mortensen JS, Ribeiro O, Hariharan P, Guan L, Loland CJ, Kobilka BK, Byrne B, Chae PS. Butane-1,2,3,4-tetraol-based amphiphilic stereoisomers for membrane protein study: importance of chirality in the linker region. Chem Sci 2017;8:1169-77. [PMID: 28451257 DOI: 10.1039/c6sc02981g] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Rawlings AE. Membrane protein engineering to the rescue. Biochem Soc Trans 2018;46:1541-9. [PMID: 30381335 DOI: 10.1042/BST20180140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Lu M, Wu B. Structural studies of G protein-coupled receptors. IUBMB Life 2016;68:894-903. [PMID: 27766738 DOI: 10.1002/iub.1578] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
52 Lessel U, Ferrara M, Heine N, Marelli C, Carrettoni L, Pfau R, Schmidt E, Riether D. Identification of Highly Selective Orexin 1 Receptor Antagonists Driven by Structure-Based Design. J Chem Inf Model 2021;61:5893-905. [PMID: 34817173 DOI: 10.1021/acs.jcim.1c01055] [Reference Citation Analysis]
53 Vitale RM, Iannotti FA, Schiano Moriello A, Tunisi L, Piscitelli F, Savopoulos R, Cristino L, De Petrocellis L, Amodeo P, Gray R, Di Marzo V. Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules 2021;11:1134. [PMID: 34439801 DOI: 10.3390/biom11081134] [Reference Citation Analysis]
54 Lee Y, Basith S, Choi S. Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. J Med Chem 2018;61:1-46. [PMID: 28657745 DOI: 10.1021/acs.jmedchem.6b01453] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 9.2] [Reference Citation Analysis]
55 Habgood M, James T, Heifetz A. Conformational Searching with Quantum Mechanics. In: Heifetz A, editor. Quantum Mechanics in Drug Discovery. New York: Springer US; 2020. pp. 207-29. [DOI: 10.1007/978-1-0716-0282-9_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Wang T, Wang Y, Tang L, Duan Y, Liu H. 7×7 RMSD matrix: A new method for quantitative comparison of the transmembrane domain structures in the G-protein coupled receptors. J Struct Biol 2017;199:87-101. [PMID: 28223044 DOI: 10.1016/j.jsb.2017.02.005] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
57 Waltenspühl Y, Schöppe J, Ehrenmann J, Kummer L, Plückthun A. Crystal structure of the human oxytocin receptor. Sci Adv 2020;6:eabb5419. [PMID: 32832646 DOI: 10.1126/sciadv.abb5419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
58 Mitsumoto M, Sugaya K, Kazama K, Nakano R, Kosugi T, Murata T, Koga N. State-Targeting Stabilization of Adenosine A2A Receptor by Fusing a Custom-Made De Novo Designed α-Helical Protein. Int J Mol Sci 2021;22:12906. [PMID: 34884716 DOI: 10.3390/ijms222312906] [Reference Citation Analysis]
59 Yang DH, Zhou CH, Liu Q, Wang MW. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure. Acta Pharmacol Sin 2015;36:1033-42. [PMID: 26279155 DOI: 10.1038/aps.2015.78] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
60 Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y, Lehmann S. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci Rep 2016;6:25162. [PMID: 27165941 DOI: 10.1038/srep25162] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
61 Dong YJ, Jiang NH, Zhan LH, Teng X, Fang X, Lin MQ, Xie ZY, Luo R, Li LZ, Li B, Zhang BB, Lv GY, Chen SH. Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis. Biomed Pharmacother 2021;143:112141. [PMID: 34509822 DOI: 10.1016/j.biopha.2021.112141] [Reference Citation Analysis]
62 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
63 Pandey A, Shin K, Patterson RE, Liu XQ, Rainey JK. Current strategies for protein production and purification enabling membrane protein structural biology. Biochem Cell Biol 2016;94:507-27. [PMID: 27010607 DOI: 10.1139/bcb-2015-0143] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
64 Wei H, Guan YD, Zhang LX, Liu S, Lu AP, Cheng Y, Cao DS. A combinatorial target screening strategy for deorphaning macromolecular targets of natural product. Eur J Med Chem 2020;204:112644. [PMID: 32738412 DOI: 10.1016/j.ejmech.2020.112644] [Reference Citation Analysis]
65 Krumm BE, Grisshammer R. Peptide ligand recognition by G protein-coupled receptors. Front Pharmacol 2015;6:48. [PMID: 25852552 DOI: 10.3389/fphar.2015.00048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
66 Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, Kotz CM, Zhang Y. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. J Med Chem 2021;64:8806-25. [PMID: 34101446 DOI: 10.1021/acs.jmedchem.1c00841] [Reference Citation Analysis]
67 Milić D, Veprintsev DB. Large-scale production and protein engineering of G protein-coupled receptors for structural studies. Front Pharmacol 2015;6:66. [PMID: 25873898 DOI: 10.3389/fphar.2015.00066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
68 Jacobson KA. New paradigms in GPCR drug discovery. Biochem Pharmacol 2015;98:541-55. [PMID: 26265138 DOI: 10.1016/j.bcp.2015.08.085] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 16.0] [Reference Citation Analysis]
69 Walker LC, Ch’ng SS, Lawrence AJ. Role of Lateral Hypothalamic Orexin (Hypocretin) Neurons in Alcohol Use and Abuse: Recent Advances. Curr Pharmacol Rep 2016;2:241-52. [DOI: 10.1007/s40495-016-0069-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, Hashmi SD, Watson NF. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med 2021;17:1895-945. [PMID: 34743790 DOI: 10.5664/jcsm.9326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
71 Ehsan M, Wang H, Cecchetti C, Mortensen JS, Du Y, Hariharan P, Nygaard A, Lee HJ, Ghani L, Guan L, Loland CJ, Byrne B, Kobilka BK, Chae PS. Maltose-bis(hydroxymethyl)phenol (MBPs) and Maltose-tris(hydroxymethyl)phenol (MTPs) Amphiphiles for Membrane Protein Stability. ACS Chem Biol 2021;16:1779-90. [PMID: 34445864 DOI: 10.1021/acschembio.1c00578] [Reference Citation Analysis]
72 Talele TT. The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. J Med Chem 2016;59:8712-56. [PMID: 27299736 DOI: 10.1021/acs.jmedchem.6b00472] [Cited by in Crossref: 314] [Cited by in F6Publishing: 222] [Article Influence: 52.3] [Reference Citation Analysis]
73 Bai Q, Pérez-Sánchez H, Shi Z, Li L, Shi D, Liu H, Yao X. Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations. Chem Biol Drug Des 2018;92:1221-31. [PMID: 29450984 DOI: 10.1111/cbdd.13181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
74 Spiegelhalder K, Nissen C, Riemann D. Clinical Sleep-Wake Disorders II: Focus on Insomnia and Circadian Rhythm Sleep Disorders. Handb Exp Pharmacol 2019;253:261-76. [PMID: 28707143 DOI: 10.1007/164_2017_40] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
75 Mezeiova E, Janockova J, Konecny J, Kobrlova T, Benkova M, Dolezal R, Prchal L, Karasova-Zdarova J, Soukup O, Korabecny J. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia. Bioorg Chem 2020;103:104179. [PMID: 32891860 DOI: 10.1016/j.bioorg.2020.104179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Schöppe J, Ehrenmann J, Klenk C, Rucktooa P, Schütz M, Doré AS, Plückthun A. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists. Nat Commun 2019;10:17. [PMID: 30604743 DOI: 10.1038/s41467-018-07939-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
77 Tikhonova IG, Gigoux V, Fourmy D. Understanding Peptide Binding in Class A G Protein-Coupled Receptors. Mol Pharmacol 2019;96:550-61. [PMID: 31436539 DOI: 10.1124/mol.119.115915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
78 Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
79 Bae HE, Du Y, Hariharan P, Mortensen JS, Kumar KK, Ha B, Das M, Lee HS, Loland CJ, Guan L, Kobilka BK, Chae PS. Asymmetric maltose neopentyl glycol amphiphiles for a membrane protein study: effect of detergent asymmetricity on protein stability. Chem Sci 2019;10:1107-16. [PMID: 30774908 DOI: 10.1039/c8sc02560f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
80 Chen S, Lu M, Liu D, Yang L, Yi C, Ma L, Zhang H, Liu Q, Frimurer TM, Wang MW, Schwartz TW, Stevens RC, Wu B, Wüthrich K, Zhao Q. Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography. Nat Commun 2019;10:638. [PMID: 30733446 DOI: 10.1038/s41467-019-08568-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
81 Massink A, Amelia T, Karamychev A, IJzerman AP. Allosteric modulation of G protein-coupled receptors by amiloride and its derivatives. Perspectives for drug discovery? Med Res Rev 2020;40:683-708. [PMID: 31495942 DOI: 10.1002/med.21633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
82 Geiger J, Sexton R, Al-Sahouri Z, Lee MY, Chun E, Harikumar KG, Miller LJ, Beckstein O, Liu W. Evidence that specific interactions play a role in the cholesterol sensitivity of G protein-coupled receptors. Biochim Biophys Acta Biomembr 2021;1863:183557. [PMID: 33444621 DOI: 10.1016/j.bbamem.2021.183557] [Reference Citation Analysis]
83 Heifetz A, Aldeghi M, Chudyk EI, Fedorov DG, Bodkin MJ, Biggin PC. Using the fragment molecular orbital method to investigate agonist-orexin-2 receptor interactions. Biochem Soc Trans 2016;44:574-81. [PMID: 27068972 DOI: 10.1042/BST20150250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
84 Karhu L, Turku A, Xhaard H. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes. BMC Struct Biol 2015;15:9. [PMID: 25957175 DOI: 10.1186/s12900-015-0036-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
85 Gacasan SB, Baker DL, Parrill AL. G protein-coupled receptors: the evolution of structural insight. AIMS Biophys 2017;4:491-527. [PMID: 29951585 DOI: 10.3934/biophy.2017.3.491] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
86 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
87 Nicole P, Couvineau P, Jamin N, Voisin T, Couvineau A. Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol 2015;172:5211-23. [PMID: 26282891 DOI: 10.1111/bph.13287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
88 Kricker JA, Page CP, Gardarsson FR, Baldursson O, Gudjonsson T, Parnham MJ. Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacol Rev 2021;73:233-62. [PMID: 34716226 DOI: 10.1124/pharmrev.121.000300] [Reference Citation Analysis]
89 Chantreau V, Taddese B, Munier M, Gourdin L, Henrion D, Rodien P, Chabbert M. Molecular Insights into the Transmembrane Domain of the Thyrotropin Receptor. PLoS One 2015;10:e0142250. [PMID: 26545118 DOI: 10.1371/journal.pone.0142250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
90 Lyons JA, Shahsavar A, Paulsen PA, Pedersen BP, Nissen P. Expression strategies for structural studies of eukaryotic membrane proteins. Current Opinion in Structural Biology 2016;38:137-44. [DOI: 10.1016/j.sbi.2016.06.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
91 Wang QQ, Wang CM, Cheng BH, Yang CQ, Bai B, Chen J. Signaling transduction regulated by 5-hydroxytryptamine 1A receptor and orexin receptor 2 heterodimers. Cell Signal 2019;54:46-58. [PMID: 30481562 DOI: 10.1016/j.cellsig.2018.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Turku A, Borrel A, Leino TO, Karhu L, Kukkonen JP, Xhaard H. Pharmacophore Model To Discover OX 1 and OX 2 Orexin Receptor Ligands. J Med Chem 2016;59:8263-75. [DOI: 10.1021/acs.jmedchem.6b00333] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
93 Pan W, Mao L, Shi M, Fu Y, Jiang X, Feng W, He Y, Xu D, Yuan L. The cytochrome c –cyclo[6]aramide complex as a supramolecular catalyst in methanol. New J Chem 2018;42:3857-66. [DOI: 10.1039/c7nj02741a] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
94 Hussain H, Helton T, Du Y, Mortensen JS, Hariharan P, Ehsan M, Byrne B, Loland CJ, Kobilka BK, Guan L, Chae PS. A comparative study of branched and linear mannitol-based amphiphiles on membrane protein stability. Analyst 2018;143:5702-10. [PMID: 30334564 DOI: 10.1039/c8an01408f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Zhao J, Deng Y, Jiang Z, Qing H. G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. Front Aging Neurosci 2016;8:58. [PMID: 27047374 DOI: 10.3389/fnagi.2016.00058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
96 Ballante F, Kooistra AJ, Kampen S, de Graaf C, Carlsson J. Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You? Pharmacol Rev 2021;73:527-65. [PMID: 34907092 DOI: 10.1124/pharmrev.120.000246] [Reference Citation Analysis]
97 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
98 Heifetz A, Chudyk EI, Gleave L, Aldeghi M, Cherezov V, Fedorov DG, Biggin PC, Bodkin MJ. The Fragment Molecular Orbital Method Reveals New Insight into the Chemical Nature of GPCR–Ligand Interactions. J Chem Inf Model 2016;56:159-72. [DOI: 10.1021/acs.jcim.5b00644] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 10.1] [Reference Citation Analysis]
99 Zhang D, Zhao Q, Wu B. Structural Studies of G Protein-Coupled Receptors. Mol Cells 2015;38:836-42. [PMID: 26467290 DOI: 10.14348/molcells.2015.0263] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
100 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
101 Gunera J, Baker JG, van Hilten N, Rosenbaum DM, Kolb P. Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor. J Med Chem 2020;63:11045-53. [PMID: 32977721 DOI: 10.1021/acs.jmedchem.0c00964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Tzoupis H, Nteli A, Platts J, Mantzourani E, Tselios T. Refinement of the gonadotropin releasing hormone receptor I homology model by applying molecular dynamics. Journal of Molecular Graphics and Modelling 2019;89:147-55. [DOI: 10.1016/j.jmgm.2019.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Doré AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J Med Chem 2020;63:1528-43. [PMID: 31860301 DOI: 10.1021/acs.jmedchem.9b01787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
104 Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther 2017;362:287-95. [PMID: 28559480 DOI: 10.1124/jpet.117.241422] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
105 Norwood VM 4th, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, Ratnayake R, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW 3rd. Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. J Med Chem 2020;63:5119-38. [PMID: 31913038 DOI: 10.1021/acs.jmedchem.9b01924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
106 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem 2020;15:2286-305. [PMID: 32937014 DOI: 10.1002/cmdc.202000453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
108 Yamamoto N, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring. Bioorganic & Medicinal Chemistry 2019;27:1747-58. [DOI: 10.1016/j.bmc.2019.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
109 Yin J, Rosenbaum DM. The Human Orexin/Hypocretin Receptor Crystal Structures. Curr Top Behav Neurosci 2017;33:1-15. [PMID: 28025809 DOI: 10.1007/7854_2016_52] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
110 Zhang Y, Borrel A, Ghemtio L, Regad L, Boije af Gennäs G, Camproux A, Yli-kauhaluoma J, Xhaard H. Structural Isosteres of Phosphate Groups in the Protein Data Bank. J Chem Inf Model 2017;57:499-516. [DOI: 10.1021/acs.jcim.6b00519] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
111 Leino TO, Turku A, Yli-kauhaluoma J, Kukkonen JP, Xhaard H, Wallén EA. Azulene-based compounds for targeting orexin receptors. European Journal of Medicinal Chemistry 2018;157:88-100. [DOI: 10.1016/j.ejmech.2018.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
112 Errey JC, Fiez-vandal C. Production of membrane proteins in industry: The example of GPCRs. Protein Expression and Purification 2020;169:105569. [DOI: 10.1016/j.pep.2020.105569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
113 Maehara S, Yuge N, Higashi C, Ota T, Furukawa J, Takeuchi T. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Neuropsychopharmacol Rep 2020;40:182-9. [PMID: 32337858 DOI: 10.1002/npr2.12105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Deflorian F, Perez-Benito L, Lenselink EB, Congreve M, van Vlijmen HWT, Mason JS, Graaf C, Tresadern G. Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation. J Chem Inf Model 2020;60:5563-79. [PMID: 32539374 DOI: 10.1021/acs.jcim.0c00449] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
115 Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuermann TH, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman PJ, Rosenbaum DM. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat Struct Mol Biol 2016;23:293-9. [PMID: 26950369 DOI: 10.1038/nsmb.3183] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
116 Yin W, Zhou XE, Yang D, de Waal PW, Wang M, Dai A, Cai X, Huang CY, Liu P, Wang X, Yin Y, Liu B, Zhou Y, Wang J, Liu H, Caffrey M, Melcher K, Xu Y, Wang MW, Xu HE, Jiang Y. Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. Cell Discov 2018;4:12. [PMID: 29560272 DOI: 10.1038/s41421-018-0009-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 8.8] [Reference Citation Analysis]
117 Cooke RM, Brown AJ, Marshall FH, Mason JS. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discovery Today 2015;20:1355-64. [DOI: 10.1016/j.drudis.2015.08.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 15.0] [Reference Citation Analysis]
118 Cavasotto CN, Palomba D. Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models. Chem Commun 2015;51:13576-94. [DOI: 10.1039/c5cc05050b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 5.1] [Reference Citation Analysis]
119 Stenkamp RE. Identifying G protein-coupled receptor dimers from crystal packings. Acta Crystallogr D Struct Biol 2018;74:655-70. [PMID: 29968675 DOI: 10.1107/S2059798318008136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
120 Ritler A, Shoshan MS, Deupi X, Wilhelm P, Schibli R, Wennemers H, Béhé M. Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2. Bioconjug Chem 2019;30:657-66. [PMID: 30608664 DOI: 10.1021/acs.bioconjchem.8b00849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
121 Ribeiro JML, Filizola M. Insights From Molecular Dynamics Simulations of a Number of G-Protein Coupled Receptor Targets for the Treatment of Pain and Opioid Use Disorders. Front Mol Neurosci 2019;12:207. [PMID: 31507375 DOI: 10.3389/fnmol.2019.00207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
122 Rosa M, Caltabiano G, Barreto-Valer K, Gonzalez-Nunez V, Gómez-Tamayo JC, Ardá A, Jiménez-Barbero J, Pardo L, Rodríguez RE, Arsequell G, Valencia G. Modulation of the Interaction between a Peptide Ligand and a G Protein-Coupled Receptor by Halogen Atoms. ACS Med Chem Lett 2015;6:872-6. [PMID: 26288687 DOI: 10.1021/acsmedchemlett.5b00126] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
123 Pappalardo M, Rayan M, Abu-Lafi S, Leonardi ME, Milardi D, Guccione S, Rayan A. Homology-based Modeling of Rhodopsin-like Family Members in the Inactive State: Structural Analysis and Deduction of Tips for Modeling and Optimization. Mol Inform 2017;36. [PMID: 28375549 DOI: 10.1002/minf.201700014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
124 Shiimura Y, Horita S, Hamamoto A, Asada H, Hirata K, Tanaka M, Mori K, Uemura T, Kobayashi T, Iwata S, Kojima M. Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode. Nat Commun 2020;11:4160. [PMID: 32814772 DOI: 10.1038/s41467-020-17554-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
125 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
126 Owen TS, Salom D, Sun W, Palczewski K. Increasing the Stability of Recombinant Human Green Cone Pigment. Biochemistry 2018;57:1022-30. [PMID: 29320632 DOI: 10.1021/acs.biochem.7b01118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
127 Heifetz A, Bodkin MJ, Biggin PC. Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists. J Med Chem 2015;58:7928-30. [PMID: 26375584 DOI: 10.1021/acs.jmedchem.5b01394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
128 Skudlarek JW, Dimarco CN, Babaoglu K, Roecker AJ, Bruno JG, Pausch MA, O'brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Wuelfing WP, Garson SL, Fox SV, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Kuduk SD, Coleman PJ. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2017;27:1364-70. [DOI: 10.1016/j.bmcl.2017.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
129 Yan W, Cheng L, Wang W, Wu C, Yang X, Du X, Ma L, Qi S, Wei Y, Lu Z, Yang S, Shao Z. Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode. Nat Commun 2020;11:5287. [PMID: 33082324 DOI: 10.1038/s41467-020-19109-w] [Reference Citation Analysis]